A PHASE 3B, OPEN LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF NOVARTIS MENINGOCOCCAL B RECOMBINANT VACCINE WHEN ADMINISTERED ALONE TO HEALTHY INFANTS ACCORDING TO DIFFERENT IMMUNIZATION SCHEDULES AND TO HEALTHY CHILDREN AGED 2 TO 10 YEARS: